
Nina Bhardwaj, MD, PhD
About Me
Nina Bhardwaj MD, PhD, is Professor of Medicine (Hematology and Medical Oncology) and Urology. She is the Director of Immunotherapy, Medical Director of the Vaccine and Cell Therapy Laboratory, and Co-Director of the Cancer Immunology Program at the Mount Sinai Tisch Cancer Center. She is a faculty member of the Icahn Genomics Institute. Dr. Bhardwaj holds the Ward Coleman Chair in Cancer Research.
Dr. Bhardwaj has made seminal contributions to human dendritic cell biology, specifically with respect to their isolation, subset discovery, immunobiology, antigen presenting function, and use of vaccine adjuvants in humans. She developed Toll Like Receptor agonist- and dendritic cell-based vaccines for the treatment of both cancer and infection in several investigator-initiated studies and has pioneered neoantigen vaccine studies at The Tisch Cancer Institute. Dr. Bhardwaj translates basic science advancements into clinically relevant patient trials.
Dr. Bhardwaj was named one of the Scientific American’s Top 50 Researchers, receiving the Award for Medical Research in 2004. She received the Fred W. Alt Award for new discoveries in Immunology in 2015 from the Cancer Research Institute. Dr. Bhardwaj is a senior editor for Cancer Immunology Research and Frontiers in Immunology. She has served on numerous NIH Study Sections and advisory councils, and was formerly chair of the Cancer Immunology Steering Committee of the American Association for Cancer Research. Dr. Bhardwaj has successfully secured multiple federal and foundation grants and has authored more than 200 publications.
For more information, visit our laboratory page at http://icahn.mssm.edu/research/labs/bhardwaj-laboratory
Dr. Bhardwaj is on Twitter at @BhardwajLab
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology, PROFESSOR | Urology, PROFESSOR | Immunology & Immunotherapy
Research Topics
AIDS/HIV, Immunology
Multi-Disciplinary Training Areas
Immunology [IMM]
Video
Education
MD, New York University School of Medicine
PhD, New York University School of Medicine
Internship, Brigham and Womens Hospital, Harvard Medical School,
Awards
New award
Publications
Selected Publications
- Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms. Charles Hertz, Nikolaos Spyrou, Ronald Hoffman, Cansu Cimen Bozkus, Nina Bhardwaj, Douglas Tremblay, Marina Kremyanskaya, John Mascarenhas. Leukemia
- Improving peptide vaccine manufacturability without sacrificing immunogenicity: substitution of methionine and cysteine with oxidation-resistant isosteres. Andrew S. Ishizuka, Christopher M. Garliss, Robert N. Goddu, Maria Merolle, Alec Schrager, Andrei Ramirez-Valdez, Qiuyin Ren, Faezzah Baharom, Matthew Essandoh, Nicholas G. Palacorolla, John P. Finnigan, Daniel C. Douek, Nina Bhardwaj, Robert A. Seder, Geoffrey M. Lynn, David R. Wilson. Journal of Immunology
- Leveraging cDC1 biology and function for enhanced immunotherapy. Ross W. Ward, Uddipan Kar, Sreekumar Balan, Nina Bhardwaj. The Journal of experimental medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Bhardwaj during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services
Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership- Merck & Co., Inc.
- National Cancer Advisory Board
- carisma
- Cell BioEngines
- apriicty
- Aikium
- Epitopea
Equity
(Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)- genotwin
- Cell BioEngines
- apriicty
- primevax
- Breakbio
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.